The antibody–drug conjugate polatuzumab vedotin-piiq (Polivy) added to R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) achieved a 27% reduction in the risk for progression or death compared with the standard regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy for patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL).
Treatment with time-limited venetoclax (Venclexta)-based combination regimens resulted in superior rates of undetectable minimal residual disease (uMRD) in the peripheral blood at 15 months compared with chemoimmunotherapy (CIT) in fit patients with chronic lymphocytic leukemia (CLL), according to findings from the GAIA (CLL13) clinical trial.
Treatment with the investigational agent mosunetuzumab (RG7828) as monotherapy induced deep remissions in patients with relapsed/refractory follicular lymphoma, according to results of a recent trial presented at the ASH 2021 Annual Meeting and Exposition.
Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies
Results from 2 single-center studies presented at the ASH 2021 Annual Meeting and Exposition showed that nearly 1 in 6 patients with hematologic diseases had no or low antibody response after a second COVID-19 vaccination, but that the mRNA 1273 COVID-19 vaccine induced a strong antibody response in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The results from 2 phase 3 clinical trials highlighted the superiority of CAR T-cell therapies over current standard of care (SOC) when used earlier in the course of treatment for patients with large B-cell lymphoma (LBCL).
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
The current study found no clear evidence linking eltrombopag treatment and risk for cataract development/progression in patients with chronic immune thrombocytopenia (ITP).
The current post-hoc subanalysis of a phase 4 open-label study concluded that the effects on platelet counts after eltrombopag treatment for >2 years was comparable between the persistent immune thrombocytopenia (ITP) and the chronic ITP cohorts, with similar safety profiles.
These study results showed that heavily pretreated patients with persistent/chronic immune thrombocytopenia (ITP) who achieved a stable response with fostamatinib therapy maintained their responses for ≥12 months.
Results of this randomized, placebo-controlled phase 3 trial showed that avatrombopag was superior to placebo in terms of the cumulative number of weeks with a platelet response, platelet response at day 8, and durability of platelet response in patients with refractory chronic immune thrombocytopenia (ITP).
This open-label study reported that the majority of children with immune thrombocytopenia (ITP) who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 109/L from week 12 onward and no new safety signals observed during the study period.
Page 1 of 12
Results 1 - 10 of 111
Results 1 - 10 of 111